Skip to content
2000
Volume 16, Issue 1
  • ISSN: 2210-3155
  • E-ISSN: 2210-3163

Abstract

Traditional Chinese medicine has used berberine (BBR) for a long time. Berberine is a natural compound found in several plants, including Royle, DC, Palib., L., , (Fort.) Carr., and L. Berberine is believed to help treat many diseases, such as ovarian and colorectal cancer, high blood pressure, Parkinson's and Alzheimer's disease, diabetes, heart disorders, depression, viral infections, and inflammatory diseases. However, when taken orally, berberine quickly breaks down in the body, leading to low levels in the bloodstream. This means that its absorption in the intestines is limited, which reduces its effectiveness despite its potential health benefits. The liver is the main organ that processes and uses berberine in both animals and humans, and about 84% of berberine and its byproducts are excreted in the feces. We thoroughly reviewed the available research on berberine from reliable sources like PubMed, ScienceDirect, ClinicalTrials.gov, and Scopus. Our study summarizes the latest findings on the therapeutic benefits of berberine and provides updated information on clinical research and patents. This review covers the various pharmacological effects of berberine, including its use in treating Alzheimer's disease, high blood pressure, neuroprotective effects, anti-arrhythmia, Parkinson's disease, diabetes, cancer, and depression.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/npj/10.2174/0122103155324599241028163050
2024-11-04
2025-10-22

  • From This Site

    /content/journals/npj/10.2174/0122103155324599241028163050
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. QinZ. TangR. LiangJ. JiaX. Berberine, a natural alkaloid: Advances in its pharmacological effects and mechanisms in the treatment of autoimmune diseases.Int. Immunopharmacol.202413711242210.1016/j.intimp.2024.11242238880024
     [Google Scholar]
  2. YazdanpanahE. DadfarS. ShadabA. OroojiN. NematiM. PazokiA. EsmaeiliS.A. BaharlouR. HaghmoradD. Berberine: A natural modulator of immune cells in multiple sclerosis.Immun. Inflamm. Dis.2024123e121310.1002/iid3.121338477663
     [Google Scholar]
  3. XiaL.M. LuoM.H. Study progress of berberine for treating cardiovascular disease.Chronic Dis. Transl. Med.20161423123529063012
     [Google Scholar]
  4. ImenshahidiM. HosseinzadehH. Berberine and barberry (Berberis vulgaris): A clinical review.Phytother. Res.201933350452310.1002/ptr.625230637820
     [Google Scholar]
  5. CuiY. ZhouQ. JinM. JiangS. ShangP. DongX. LiL. Research progress on pharmacological effects and bioavailability of berberine.Naunyn Schmiedebergs Arch. Pharmacol.202410.1007/s00210‑024‑03199‑038888754
     [Google Scholar]
  6. MaX. YuX. LiR. CuiJ. YuH. RenL. JiangJ. ZhangW. WangL. Berberine-silybin salt achieves improved anti-nonalcoholic fatty liver disease effect through regulating lipid metabolism.J. Ethnopharmacol.2024319Pt 211723810.1016/j.jep.2023.11723837774895
     [Google Scholar]
  7. YeY. LiuX. WuN. HanY. WangJ. YuY. ChenQ. Efficacy and safety of berberine alone for several metabolic disorders: A systematic review and meta-analysis of randomized clinical trials.Front. Pharmacol.20211265388710.3389/fphar.2021.65388733981233
     [Google Scholar]
  8. YuH. ZhangS. LiR. MaC. ZhangQ. XiaF. ZhouB. XieZ. LiaoZ. Berberine alleviates inflammation and suppresses PLA2-COX-2-PGE2-EP2 pathway through targeting gut microbiota in DSS-induced ulcerative colitis.Biochem. Biophys. Res. Commun.202469514941110.1016/j.bbrc.2023.14941138154262
     [Google Scholar]
  9. SuadoniM.T. AthertonI. Berberine for the treatment of hypertension: A systematic review.Complement. Ther. Clin. Pract.20214210128710.1016/j.ctcp.2020.10128733461163
     [Google Scholar]
  10. MengF.C. WuZ.F. YinZ.Q. LinL.G. WangR. ZhangQ.W. Coptidis rhizoma and its main bioactive components: recent advances in chemical investigation, quality evaluation and pharmacological activity.Chin. Med.20181311310.1186/s13020‑018‑0171‑329541156
     [Google Scholar]
  11. WangJ. WangL. LouG.H. ZengH.R. HuJ. HuangQ.W. PengW. YangX.B. Coptidis Rhizoma: A comprehensive review of its traditional uses, botany, phytochemistry, pharmacology and toxicology.Pharm. Biol.201957119322510.1080/13880209.2019.157746630963783
     [Google Scholar]
  12. GaoY. NieK. WangH. DongH. TangY. Research progress on antidepressant effects and mechanisms of berberine.Front. Pharmacol.202415133144010.3389/fphar.2024.133144038318145
     [Google Scholar]
  13. DavoodvandiA. SadeghiS. AlaviS.M.A. AlaviS.S. JafariA. KhanH. AschnerM. MirzaeiH. SharifiM. AsemiZ. The therapeutic effects of berberine for gastrointestinal cancers.Asia Pac. J. Clin. Oncol.202420215216710.1111/ajco.1394136915942
     [Google Scholar]
  14. LiangY. XuX. YinM. ZhangY. HuangL. ChenR. NiJ. Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: A systematic literature review and a meta-analysis.Endocr. J.2019661516310.1507/endocrj.EJ18‑010930393248
     [Google Scholar]
  15. PangB. ZhaoL.H. ZhouQ. ZhaoT.Y. WangH. GuC.J. TongX.L. Application of berberine on treating type 2 diabetes mellitus.Int. J. Endocrinol.20152015190574910.1155/2015/905749
     [Google Scholar]
  16. KimS. LeeS.Y. ChoH.J. Berberine and zinc oxide-based nanoparticles for the chemo-photothermal therapy of lung adenocarcinoma.Biochem. Biophys. Res. Commun.2018501376577010.1016/j.bbrc.2018.05.06329758197
     [Google Scholar]
  17. CazzanigaM. BonanniB. Relationship between metabolic disorders and breast cancer incidence and outcomes. Is there a preventive and therapeutic role for berberine?Anticancer Res.20183884393440210.21873/anticanres.1274130061203
     [Google Scholar]
  18. LiJ. TianY. ZhaoL. WangY. ZhangH. XuD. ZhaoX. LiY. Berberine inhibits androgen synthesis by interaction with aldo-keto reductase 1C3 in 22Rv1 prostate cancer cells.Asian J. Androl.201618460761210.4103/1008‑682X.16999726698234
     [Google Scholar]
  19. WenB. HuangC. WuL. LiuH. Effect of evodiamine and berberine on miR-429 as an oncogene in human colorectal cancer.OncoTargets Ther.201694121412710.2147/OTT.S10472927462166
     [Google Scholar]
  20. HuQ. LiL. ZouX. XuL. YiP. Berberine attenuated proliferation, invasion and migration by targeting the AMPK/HNF4α/WNT5A pathway in gastric carcinoma.Front. Pharmacol.20189115010.3389/fphar.2018.0115030405404
     [Google Scholar]
  21. BehlT. SinghS. SharmaN. ZahoorI. AlbarratiA. AlbrattyM. MerayaA.M. NajmiA. BungauS. Expatiating the pharmacological and nanotechnological aspects of the alkaloidal drug berberine: Current and future trends.Molecules20222712370510.3390/molecules2712370535744831
     [Google Scholar]
  22. CiceroA.F. BaggioniA. Berberine and its role in chronic disease.Anti-inflammatory Nutraceuticals and Chronic Diseases20162745SpringerCham GuptaS. PrasadS. AggarwalB. 10.1007/978‑3‑319‑41334‑1_2
     [Google Scholar]
  23. Ionita-RaduF. PatoniC. NancoffA.S. MarinF.S. GamanL. BucuricaA. SocolC. JingaM. DutuM. BucuricaS. Berberine effects in pre-fibrotic stages of non-alcoholic fatty liver disease - Clinical and pre-clinical overview and systematic review of the literature.Int. J. Mol. Sci.2024258420110.3390/ijms2508420138673787
     [Google Scholar]
  24. SongL. ZhangW. TangS. LuoS. XiongP. LiuJ. HuH. ChenY. JiaB. YanQ. TangS. HuangW. Natural products in traditional Chinese medicine: Molecular mechanisms and therapeutic targets of renal fibrosis and state-of-the-art drug delivery systems.Biomed. Pharmacother.202417011603910.1016/j.biopha.2023.11603938157643
     [Google Scholar]
  25. KumarA. Ekavali ChopraK. MukherjeeM. PottabathiniR. DhullD.K. Current knowledge and pharmacological profile of berberine: An update.Eur. J. Pharmacol.201576128829710.1016/j.ejphar.2015.05.06826092760
     [Google Scholar]
  26. MaJ.Y. FengR. TanX.S. MaC. ShouJ.W. FuJ. HuangM. HeC.Y. ChenS.N. ZhaoZ.X. HeW.Y. WangY. JiangJ.D. Excretion of berberine and its metabolites in oral administration in rats.J. Pharm. Sci.2013102114181419210.1002/jps.2371824006193
     [Google Scholar]
  27. LiuC.S. ZhengY.R. ZhangY.F. LongX.Y. Research progress on berberine with a special focus on its oral bioavailability.Fitoterapia201610927428210.1016/j.fitote.2016.02.00126851175
     [Google Scholar]
  28. HeJ.M. MuQ. The medicinal uses of the genus Mahonia in traditional Chinese medicine: An ethnopharmacological, phytochemical and pharmacological review.J. Ethnopharmacol.201517566868310.1016/j.jep.2015.09.01326387740
     [Google Scholar]
  29. MughalT.A. AliS. MumtazS. SummerM. SaleemM.Z. HassanA. HameedM.U. Evaluating the biological (antidiabetic) potential of TEM, FTIR, XRD, and UV-spectra observed Berberis lyceum conjugated silver nanoparticles.Microsc. Res. Tech.20248761286130510.1002/jemt.2450938351883
     [Google Scholar]
  30. HussainN. AdhikariA. AhmadM.S. WahabA. AliM. ChoudharyM.I. Two new prenylated flavonoids from the roots of Berberis thunbergii DC.Nat. Prod. Res.201731778579010.1080/14786419.2016.124419527788592
     [Google Scholar]
  31. LaamechJ. El-HilalyJ. FetouiH. ChtourouY. GouitaaH. TahraouiA. LyoussiB. Berberis vulgaris L. effects on oxidative stress and liver injury in lead-intoxicated mice.J. Complement. Integr. Med.20171412015007910.1515/jcim‑2015‑007928195545
     [Google Scholar]
  32. LeeH.Y. HeX. AhnJ. Enhancement of antimicrobial and antimutagenic activities of Korean barberry (Berberis koreana Palib.) by the combined process of high‐pressure extraction with probiotic fermentation.J. Sci. Food Agric.201090142399240410.1002/jsfa.409820672332
     [Google Scholar]
  33. DanY. LiuY. PengY. QianZ. XiaoP. New collection of crude drugs in Chinese pharmacopoeia 2010 II. Sankezhen (Berberis spp.).Chin. Herb. Med.20113426828410.3969/j.issn.1674‑6384.2011.04.006
     [Google Scholar]
  34. GilcaM. GamanL. PanaitE. StoianI. AtanasiuV. Chelidonium majus - An integrative review: Traditional knowledge versus modern findings.Forsch. Komplement. Med.201017524124810.1159/00032139720980763
     [Google Scholar]
  35. ChenM.L. XianY.F. IpS.P. TsaiS.H. YangJ.Y. CheC.T. Chemical and biological differentiation of cortex phellodendri chinensis and cortex phellodendri amurensis.Planta Med.201076141530153510.1055/s‑0030‑124977420354951
     [Google Scholar]
  36. TangJ. FengY. TsaoS. WangN. CurtainR. WangY. Berberine and Coptidis Rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations.J. Ethnopharmacol.2009126151710.1016/j.jep.2009.08.00919686830
     [Google Scholar]
  37. TsangC.M. LauE.P. DiK. CheungP.Y. HauP.M. ChingY.P. WongY.C. CheungA.L. WanT.S. TongY. TsaoS.W. FengY. Berberine inhibits Rho GTPases and cell migration at low doses but induces G2 arrest and apoptosis at high doses in human cancer cells.Int. J. Mol. Med.200924113113819513545
     [Google Scholar]
  38. ChenY.X. GaoQ.Y. ZouT.H. WangB.M. LiuS.D. ShengJ.Q. RenJ.L. ZouX.P. LiuZ.J. SongY.Y. XiaoB. SunX.M. DouX.T. CaoH.L. YangX.N. LiN. KangQ. ZhuW. XuH.Z. ChenH.M. CaoX.C. FangJ.Y. Berberine versus placebo for the prevention of recurrence of colorectal adenoma: A multicentre, double-blinded, randomised controlled study.Lancet Gastroenterol. Hepatol.20205326727510.1016/S2468‑1253(19)30409‑131926918
     [Google Scholar]
  39. TorreL.A. TrabertB. DeSantisC.E. MillerK.D. SamimiG. RunowiczC.D. GaudetM.M. JemalA. SiegelR.L. Ovarian cancer statistics, 2018.CA Cancer J. Clin.201868428429610.3322/caac.2145629809280
     [Google Scholar]
  40. BastR.C.Jr MatulonisU.A. SoodA.K. AhmedA.A. AmobiA.E. BalkwillF.R. Wielgos-BonvalletM. BowtellD.D.L. BrentonJ.D. BruggeJ.S. ColemanR.L. DraettaG.F. DobersteinK. DrapkinR.I. EckertM.A. EdwardsR.P. EliasK.M. EnnisD. FutrealA. GershensonD.M. GreenbergR.A. HuntsmanD.G. JiJ.X.Y. KohnE.C. IavaroneC. LengyelE.R. LevineD.A. LordC.J. LuZ. MillsG.B. ModugnoF. NelsonB.H. OdunsiK. PilsworthJ.A. RottapelR.K. PowellD.J.Jr ShenL. ShihI.M. SpriggsD.R. WaltonJ. ZhangK. ZhangR. ZouL. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.Cancer2019125121963197210.1002/cncr.3200430835824
     [Google Scholar]
  41. MeneesS. SaadR. CheyW.D. Agents that act luminally to treat diarrhoea and constipation.Nat. Rev. Gastroenterol. Hepatol.201291166167410.1038/nrgastro.2012.16222945441
     [Google Scholar]
  42. KongW.J. ZhangH. SongD.Q. XueR. ZhaoW. WeiJ. WangY.M. ShanN. ZhouZ.X. YangP. YouX.F. LiZ.R. SiS.Y. ZhaoL.X. PanH.N. JiangJ.D. Berberine reduces insulin resistance through protein kinase C–dependent up-regulation of insulin receptor expression.Metabolism200958110911910.1016/j.metabol.2008.08.01319059538
     [Google Scholar]
  43. SinghI.P. MahajanS. Berberine and its derivatives: A patent review (2009 – 2012).Expert Opin. Ther. Pat.201323221523110.1517/13543776.2013.74631423231038
     [Google Scholar]
  44. HuangY. WangK. GuC. YuG. ZhaoD. MaiW. ZhongY. LiuS. NieY. YangH. Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib.Oncol. Rep.20184031525153210.3892/or.2018.655230015938
     [Google Scholar]
  45. LiuQ. XuX. ZhaoM. WeiZ. LiX. ZhangX. LiuZ. GongY. ShaoC. Berberine induces senescence of human glioblastoma cells by downregulating the EGFR-MEK-ERK signaling pathway.Mol. Cancer Ther.201514235536310.1158/1535‑7163.MCT‑14‑063425504754
     [Google Scholar]
  46. KimS. YouD. JeongY. YuJ. KimS.W. NamS.J. LeeJ.E. Berberine down-regulates IL-8 expression through inhibition of the EGFR/MEK/ERK pathway in triple-negative breast cancer cells.Phytomedicine201850434910.1016/j.phymed.2018.08.00430466991
     [Google Scholar]
  47. JinP. ZhangC. LiN. Berberine exhibits antitumor effects in human ovarian cancer cells.Anticancer Agents Med. Chem.154201551151610.2174/1871520614666141226124110
     [Google Scholar]
  48. ChenQ. QinR. FangY. LiH. Berberine sensitizes human ovarian cancer cells to cisplatin through miR-93/PTEN/Akt signaling pathway.Cell. Physiol. Biochem.201536395696510.1159/00043027026087719
     [Google Scholar]
  49. MarvertiG. LigabueA. LombardiP. FerrariS. MontiM.G. FrassinetiC. CostiM.P. Modulation of the expression of folate cycle enzymes and polyamine metabolism by berberine in cisplatin-sensitive and -resistant human ovarian cancer cells.Int. J. Oncol.20134341269128010.3892/ijo.2013.204523903781
     [Google Scholar]
  50. LiuL. FanJ. AiG. LiuJ. LuoN. LiC. ChengZ. Berberine in combination with cisplatin induces necroptosis and apoptosis in ovarian cancer cells.Biol. Res.20195213710.1186/s40659‑019‑0243‑631319879
     [Google Scholar]
  51. Diabetes atlas.2003Available from: https://citeseerx.ist.psu.edu/document?repid=rep1&type=pdf&doi=63f76c94a6a5b64dc29eaa883830907934b1b2ef
  52. ChangW. ChenL. HatchG.M. Berberine as a therapy for type 2 diabetes and its complications: From mechanism of action to clinical studies.Biochem. Cell Biol.201593547948610.1139/bcb‑2014‑010725607236
     [Google Scholar]
  53. YangW.L. ZhangC.Y. JiW.Y. ZhaoL.L. YangF.Y. ZhangL. CaoX. Berberine metabolites stimulate GLP-1 secretion by alleviating oxidative stress and mitochondrial dysfunction.Am. J. Chin. Med.202452125327410.1142/S0192415X2450011338351702
     [Google Scholar]
  54. LanJ. ZhaoY. DongF. YanZ. ZhengW. FanJ. SunG. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension.J. Ethnopharmacol.2015161698110.1016/j.jep.2014.09.04925498346
     [Google Scholar]
  55. CiceroA.F.G. FogacciF. CollettiA. Food and plant bioactives for reducing cardiometabolic disease risk: An evidence based approach.Food Funct.2017862076208810.1039/C7FO00178A28541356
     [Google Scholar]
  56. CalicetiC. FrancoP. SpinozziS. RodaA. CiceroA.F.G. Berberine: New insights from pharmacological aspects to clinical evidences in the management of metabolic disorders.Curr. Med. Chem.201623141460147610.2174/092986732366616041114331427063256
     [Google Scholar]
  57. LuoJ. GuY. LiuP. JiangX. YuW. YeP. ChaoY. YangH. ZhuL. ZhouL. ChenS. Berberine attenuates pulmonary arterial hypertension via protein phosphatase 2A signaling pathway both in vivo and in vitro.J. Cell. Physiol.2018233129750976210.1002/jcp.2694030078229
     [Google Scholar]
  58. ShenJ. MaL. HuC. PeiY. JinS. FangX. LiY. Berberine up-regulates the BDNF expression in hippocampus and attenuates corticosterone-induced depressive-like behavior in mice.Neurosci. Lett.2016614778210.1016/j.neulet.2016.01.00226773864
     [Google Scholar]
  59. BarangiS. HayesA.W. KarimiG. The more effective treatment of atrial fibrillation applying the natural compounds; As NADPH oxidase and ion channel inhibitors.Crit. Rev. Food Sci. Nutr.20185871230124110.1080/10408398.2017.137900028925721
     [Google Scholar]
  60. ChenC. YuZ. LiY. FichnaJ. StorrM. Effects of berberine in the gastrointestinal tract - A review of actions and therapeutic implications.Am. J. Chin. Med.20144251053107010.1142/S0192415X1450066925183302
     [Google Scholar]
  61. HuangWM WuZD GanYQ Effects of berberine on ischemic ventricular arrhythmia. Zhonghua Xin Xue Guan Bing Za Zhi.198917300319
     [Google Scholar]
  62. ZhangC. LiC. ChenS. LiZ. JiaX. WangK. BaoJ. LiangY. WangX. ChenM. LiP. SuH. WanJ.B. LeeS.M.Y. LiuK. HeC. Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K/AKT/Bcl-2 and Nrf2/HO-1 pathways.Redox Biol.20171111110.1016/j.redox.2016.10.01927835779
     [Google Scholar]
  63. SadraieS. KiasalariZ. RazavianM. AzimiS. SedighnejadL. Afshin-MajdS. BaluchnejadmojaradT. RoghaniM. Berberine ameliorates lipopolysaccharide-induced learning and memory deficit in the rat: Insights into underlying molecular mechanisms.Metab. Brain Dis.201934124525510.1007/s11011‑018‑0349‑530456649
     [Google Scholar]
  64. KhezriM.R. MohammadipanahS. Ghasemnejad-BerenjiM. The pharmacological effects of Berberine and its therapeutic potential in different diseases: Role of the phosphatidylinositol 3‐kinase/AKT signaling pathway.Phytother. Res.202438134936710.1002/ptr.804037922566
     [Google Scholar]
  65. DengH. MaZ. Protective effects of berberine against MPTP-induced dopaminergic neuron injury through promoting autophagy in mice.Food Funct.202112188366837510.1039/D1FO01360B34342315
     [Google Scholar]
  66. CaiZ. WangC. YangW. Role of berberine in Alzheimer’s disease.Neuropsychiatr. Dis. Treat.2016122509252010.2147/NDT.S11484627757035
     [Google Scholar]
  67. NattelS. DobrevD. Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation.Nat. Rev. Cardiol.2016131057559010.1038/nrcardio.2016.11827489190
     [Google Scholar]
  68. SinghA.K. SinghS.K. NandiM.K. MishraG. MauryaA. RaiA. RaiG.K. AwasthiR. SharmaB. KulkarniG.T. Berberine: A plant-derived alkaloid with therapeutic potential to combat Alzheimer’s disease.Cent. Nerv. Syst. Agents Med. Chem.201919315417010.2174/1871524919666190820160053
     [Google Scholar]
  69. AkbarM. ShabbirA. RehmanK. AkashM.S.H. ShahM.A. Neuroprotective potential of berberine in modulating Alzheimer’s disease via multiple signaling pathways.J. Food Biochem.20214510e1393610.1111/jfbc.1393634523148
     [Google Scholar]
  70. SunC. DongS. ChenW. LiJ. LuoE. JiJ. Berberine alleviates Alzheimer’s disease by regulating the gut microenvironment, restoring the gut barrier and brain-gut axis balance.Phytomedicine202412915562410.1016/j.phymed.2024.15562438678955
     [Google Scholar]
  71. MatuszykM.M. GarwoodC.J. FerraiuoloL. SimpsonJ.E. StaniforthR.A. WhartonS.B. Biological and methodological complexities of beta‐amyloid peptide: Implications for Alzheimer’s disease research.J. Neurochem.2022160443445310.1111/jnc.1553834767256
     [Google Scholar]
  72. KaliaL.V. LangA.E. Parkinson’s disease.Lancet2015386999689691210.1016/S0140‑6736(14)61393‑325904081
     [Google Scholar]
  73. HouY. DanX. BabbarM. WeiY. HasselbalchS.G. CroteauD.L. BohrV.A. Ageing as a risk factor for neurodegenerative disease.Nat. Rev. Neurol.2019151056558110.1038/s41582‑019‑0244‑731501588
     [Google Scholar]
  74. ChengZ. KangC. CheS. SuJ. SunQ. GeT. GuoY. LvJ. SunZ. YangW. LiB. LiX. CuiR. Berberine: A promising treatment for neurodegenerative diseases.Front. Pharmacol.20221384559110.3389/fphar.2022.84559135668943
     [Google Scholar]
  75. ShinK.S. ChoiH.S. ZhaoT.T. SuhK.H. KwonI.H. ChoiS.O. LeeM.K. Neurotoxic effects of berberine on long-term l-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson’s disease.Arch. Pharm. Res.201336675976710.1007/s12272‑013‑0051‑423539311
     [Google Scholar]
  76. CalicetiC. RizzoP. CiceroA.F.G. Potential benefits of berberine in the management of perimenopausal syndrome.Oxid. Med. Cell. Longev.20152015172309310.1155/2015/72309325785174
     [Google Scholar]
  77. WuJ. NakashimaS. ShigyoM. YamasakiM. IkunoS. MorikawaA. TakegamiS. NakamuraS. KonishiA. KitadeT. MatsudaH. Antihypertensive constituents in Sanoshashinto.J. Nat. Med.202074242143310.1007/s11418‑019‑01382‑931894475
     [Google Scholar]
  78. SongD. HaoJ. FanD. Biological properties and clinical applications of berberine.Front. Med.202014556458210.1007/s11684‑019‑0724‑632335802
     [Google Scholar]
  79. LiuX. ZhangX. YeL. YuanH. Protective mechanisms of berberine against experimental autoimmune myocarditis in a rat model.Biomed. Pharmacother.20167922223010.1016/j.biopha.2016.02.01527044832
     [Google Scholar]
  80. FengM. ZouZ. ZhouX. HuY. MaH. XiaoY. LiX. YeX. Comparative effect of berberine and its derivative 8-cetylberberine on attenuating atherosclerosis in ApoE−/− mice.Int. Immunopharmacol.20174319520210.1016/j.intimp.2016.12.00128024280
     [Google Scholar]
  81. ChengW.-E. ChangM.Y. WeiJ.-Y. ChenY.-J. MaaM.-C. LeuT.-H. Berberine reduces toll-like receptor-mediated macrophage migration by suppression of Src enhancement.Eur. J. Pharmacol.757201511010.1016/j.ejphar.2015.03.013
     [Google Scholar]
  82. LiG. WangX. JiangT. GongJ. NiuL. LiN. Berberine prevents intestinal mucosal barrier damage during early phase of sepsis in rat through the toll-like receptors signaling pathway.Korean J. Physiol. Pharmacol.20151911710.4196/kjpp.2015.19.1.125605990
     [Google Scholar]
  83. WarowickaA. NawrotR. Goździcka-JózefiakA. Antiviral activity of berberine.Arch. Virol.202016591935194510.1007/s00705‑020‑04706‑332594322
     [Google Scholar]
  84. PangY.N. LiangY.W. FengT.S. ZhaoS. WuH. ChaiY.S. LeiF. DingY. XingD.M. DuL.J. Transportation of berberine into HepG2, HeLa and SY5Y cells: A correlation to its anti-cancer effect.PLoS One2014911e11293710.1371/journal.pone.011293725402492
     [Google Scholar]
  85. VargheseF.S. ThaaB. AmrunS.N. SimarmataD. RausaluK. NymanT.A. MeritsA. McInerneyG.M. NgL.F.P. AholaT. The antiviral alkaloid berberine reduces chikungunya virus-induced mitogen-activated protein kinase signaling.J. Virol.201690219743975710.1128/JVI.01382‑1627535052
     [Google Scholar]
  86. ShinH.B. ChoiM.S. YiC.M. LeeJ. KimN.J. InnK.S. Inhibition of respiratory syncytial virus replication and virus-induced p38 kinase activity by berberine.Int. Immunopharmacol.2015271656810.1016/j.intimp.2015.04.04525939536
     [Google Scholar]
  87. KimS.Y. KimH. KimS.W. LeeN.R. YiC.M. HeoJ. KimB.J. KimN.J. InnK.S. An effective antiviral approach targeting hepatitis B virus with NJK14047, a novel and selective biphenyl amide p38 mitogen-activated protein kinase inhibitor.Antimicrob. Agents Chemother.2017618e00214-1710.1128/AAC.00214‑1728559272
     [Google Scholar]
  88. GaoR. LuY. ZhangW. ZhangZ. The application of berberine in fibrosis and the related diseases.Am. J. Chin. Med.202452375377310.1142/S0192415X2450030738716621
     [Google Scholar]
  89. Effects of berberine in reducing abdominal visceral adipose tissue among individuals with obesity and NAFLD (BRAVO).NCT056479152022
  90. NejatiL. Berberine and non-alcoholic fatty liver disease (NAFLD).NCT040493962019
  91. Berberine effects on clinical symptoms and metabolic disturbance in patients with schizophrenia.NCT03548155>2023
  92. Bezafibrate plus berberine in mixed dyslipidemia.NCT025488322023
  93. Effect of probiotics or berberine in hepatic steatosis markers, cardiometabolic and microbiotic profile in NAFL.NCT055230242022
  94. Berberine and cinnamon in management of diabetes.NCT055703572024
  95. Helicobacter pylori eradication with berberine plus amoxicillin triple therapy versus bismuth-containing quadruple therapy.NCT046971862023
  96. Combination of danazole with berberine in the treatment of ITP.NCT039097632020
  97. Effect of berberine for endothelial function and intestinal microflora in patients with coronary artery disease.NCT044343652020
  98. Effects of berberine plus inulin on diabetes care in patients with LADA.NCT046983302022
  99. Effects of berberine hydrochloride and bifidobacterium in prediabetes prevention and treatment.NCT020827562018
  100. Therapeutic effects of berberine in patients with type 2 diabetes.NCT004250092007
  101. Berberine treat metabolic syndrome in schizophrenia.NCT032517162018
  102. Pharmacological profile of different berberine formulations, and effects on blood sugar levels.NCT053702612023
  103. Efficacy and safety of berberine in the treatment of diabetes with dyslipidemia.NCT004620462007
  104. Effect of gamma-cyclodextrin on the bioavailability of berberine.NCT049186672023
  105. Helicobacter pylori eradication with berberine quadruple therapy versus clarithromycin quadruple therapy.NCT026339302017
  106. Study on the efficacy and safety of berberine-containing triple therapy in Helicobacter pylori first-line eradication.NCT050143342023
  107. YangJ-K. Berberine hyperglycemic clamp (BBR HC).NCT039722152023
  108. Berberine as adjuvant treatment for schizophrenia patients (BER).NCT029831882021
  109. Impact of OCT1 and CYP2D6 genotypes on pharmacokinetics of berberine in healthy volunteers (BERKI-1).NCT054630032023
  110. Anti-platelet effect of berberine in patients after percutaneous coronary intervention (APLABE-PCI).NCT033789342022
  111. The absorption of bioactive berberine in human.NCT034382922021
  112. GaoX. Role of pioglitazone and berberine in treatment of non-alcoholic fatty liver disease..NCT006332822012
  113. Berberine and altered fasting glucose.NCT050317152022
  114. Effect of berberine versus metformin on glycemic control, insulin sensitivity and insulin secretion in prediabetes.NCT030293902023
  115. Endoscopic and microbiological assessment of the effect of carvedilol combined with berberine on gov in cirrhosis (CABER).NCT045436432021
  116. Bioavailability of berberine and dihydroberberine and their impact on glycemia (BBD).NCT050213412021
  117. Treatment benefits of berberine supplementation for women with PCOS.NCT054806702023
  118. Effects of berberine on preventing cardiovascular disease and diabetes mellitus (ABCD).NCT057498742023
  119. Berberine chloride in preventing colorectal cancer in patients with ulcerative colitis in remission.NCT023654802021
  120. Berberine, chlorogenic acid and tocotrienols in menopause-associated dyslipidemia.NCT030192632018
  121. Berberine, curcumin, inositol, banaba and chromium picolinate in patients with fasting dysglycemia.NCT041079872019
  122. Effect of berberine on metabolic syndrome, efficacy and safety in combination with antiretroviral therapy in PLWH. (BERMESyH).NCT048600632021
  123. Berberine prevent contrast-induced nephropathy in patients with diabetes.NCT028083512022
  124. Evaluating the tolerability and effects of berberine on major metabolic biomarkers: A pilot study.NCT039763362024
  125. A research of berberine hydrochloride to prevent colorectal adenomas in patients with previous colorectal cancer.NCT032810962022
  126. Combination of curcumin and berberine therapy in the treatment of post acute diverticulitis (SUDD).NCT055962142023
  127. Primary chemoprevention of familial adenomatous polyposis with berberine hydrochloride.NCT033332652022
  128. Study of berberine hydrochloride in prevention of colorectal adenomas recurrence.NCT022261852019
  129. Helicobacter rescue therapy with berberine plus amoxicillin quadruple therapy versus tetracycline plus furazolidone quadruple therapy.NCT036098922019
  130. The BANGALORE study; Combination of berberine, lipoic acid, and picrorhiza (CAR-191).NCT016964482014
  131. Berberine effect on cytokine, CRP, metabolic disturbance as an adjunctive therapy in schizophrenia patients.NCT029364142018
  132. Effect of BGG on glucose metabolism and other markers of metabolic syndrome (Glucogold).NCT028340782016
  133. TangY. Cardiovascular diseases and diabetes prevention programme in metabolic syndrome (CDPP).NCT051053212021
  134. Metabolic and cardiovascular effects of armolipid plus in subjects with metabolic syndrome (ARMP-11).NCT022951762015
  135. Berberine and polycystic ovary syndrome.NCT049320702021
  136. Effectiveness and safety of berberine hydrochloride and bifidobacterium in people with abnormal glucose level.NCT033301842021
  137. The effect of berberine on intestinal function and inflammatory mediators in severe patients with COVID-19 (BOIFIM).NCT044792022020
  138. Comparison of berberine and metformin for the treatment for ms in schizophrenia patients.NCT037085492022
  139. KumarS. SaharanR. SainiV. SainiA. Gallic acid: A wonderful remedy in medicinal field.Curr. Tradit. Med.202511211710.2174/0122150838266828231005055236
     [Google Scholar]
  140. DeviV. DeswalG. DassR. ChopraB KriplaniP. GrewalA.S. DhingraA.K. Hemorrhoid Disease: A review on treatment, clinical research and patent data.Infect. Disord. Drug Targets236e270423216271202310.2174/187152652366623042711543637106517
     [Google Scholar]
  141. DeviV. DeswalG. DassR. ChopraB. KriplaniP. GrewalA.S. GuarveK. DhingraA.K. Therapeutic potential and clinical effectiveness of quercetin: A dietary supplement.Recent Adv. Food Nutr. Agric.1511332202410.2174/012772574X269376231107095831
     [Google Scholar]
  142. ColmanJ. Combinations of berberine, artemisinin, loperamide and their derivatives to treat malaria, diarrhea, travelers' diarrhea, dysentery, dengue fever, parasites, cholera and viruses.US Patent 20130071474A12013
  143. DaviesG. YueshanH. Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs.US Patent 20110281852A12011
  144. NishinaY. MatsumotoE. KiyobayashiY. Berberine-containing aqueous composition.JP Patent 2008024700A2008
  145. XieY. TangY. ZhaoZ. ZhuoC. WuD. Fenofibric acid salt with berberine or its analogues, crystalline forms, methods of preparation, and applications thereof.US Patent 10577379B12020
  146. ChristineD. Composition containing berberine or a derivative thereof and an antimicrobial agent or an antibiotic agent, and their use for treating oral pathogens and other disorders.WO Patent 2004093876A22005
  147. JiaB. Berberine double salt and preparation method and application thereof.CN Patent 105294676A2017
  148. XieY. ZhaoZ. ZhengY. HuL. ChenZ. WanF. WuD. Purification method and crystal form of berberine or berberine salt.CN Patent 111205285B2021
  149. WuK. Application of high-solubility berberine in preparing medicine.CN Patent 1771944A2006
  150. David XiangY. ZhichengX. Berberine alkaloid formulations in the prevention and/or treatment of infectious disease.US Patent 20210329946A12021
  151. SuX. Berberine and fenofibrate pharmaceutical composition and use thereof.CN Patent 105560233A2018
  152. SuX. Berberine and simvastatin pharmaceutical composition and use thereof.CN Patent 105560232A2017
  153. YongK. KaiZ. SuX. ZhuY. ZhouL. LangG. WangY. Oral medicine composition consisting of berberine and melbine, and preparation method thereof.CN Patent 103271907B2014
  154. DengY. YangX. ZhangX. Berberine liposome and preparation method thereof.CN patent 102475682B2013
  155. WangY. Andrographolide and berberine combination and application thereof.CN Patent 102151260B2012
  156. GuangN. LiX. ZhangY. JieH. GuW. ZhiZ. WangW. LiH. NaZ. GuS. Use of berberine in treating metabolism complex.CN Patent 101219141A2008
  157. ShangS. MinX. LiY. LanS. Method for synthesizing berberine citrate.CN101948469B2012
  158. HanY. ZhengX. XinC. Tea tree oil-berberine antibacterial composite suspension emulsion and preparation method thereof.CN Patent 105638758A2018
  159. JiangM. WuY. ZhuX. Oral pharmaceutical composition of diacerein and berberine, and applications thereof.CN Patent 104771400A2015
  160. HeL. ZhangY. Sulfuric acid or berberine hydrochloride multivesicular liposome and preparation method thereof.CN Patent 106361702B2019
  161. ZhuX. WuY. JiangM. Oral pharmaceutical composition of diacerein and berberine.CN patent 104771401A2015
  162. LiX. DengJ. QinZ. Mangiferin-berberine composition.CN Patent 101066275A2007
  163. JunY. Medicine composition of berberine and repaglinide.CN Patent 105055413A2015
  164. XieX. LiZ. ShenZ. WangT. Pharmaceutical composition utilizing berberine to inhibit cancer stem cell growth or cancer cell metastasis, and application thereof.CN Patent 102824344A2012
  165. HengZ. LaoX. ZhouD. YuY. New application of using berberine as metal beta-lactamase inhibitor.CN Patent 105232548A2018
  166. ShuaiH. LiL. YuanF. LiL. One kind is without palatability high content berberine sulphate oral liquid and preparation method thereof.CN Patent 106729739A2017
  167. WangC. SunW. ZhengF. LuC. ZhuZ, MaoL.Z. ZhangH. ZhuM. Rhubarb yellow berberine ion-pair compound, preparation method and application.CN Patent 103319479B2015
  168. HsiehH.-M. LeeC.-Y. ShenC.C. WangT.-C. Berberine-containing pharmaceutical composition for inhibiting cancer stem cell growth or carcinoma metastasis and application thereof.US Patent 20150320738A2015
  169. BoJ. WangS. NaW. LiuX. ShuangX. A kind of Berberine hydrochloride takes orally pellet xerogel and its preparation method and application.CN Patent 106511260B2019
  170. HuangZ. GuL. YanM. 9-N-substituted berberine derivatives as well as preparation method and use as anti-cancer drugs.CN Patent 101255158B2010
  171. YeX. LiX. Long chain alkyl berberine salt derivative, synthetic method and use.CN Patent 101104618B2010
  172. ChenY. YiL. ChenJ. GaoJ. QianC. WenC. Berberine organic acid salt, berberine organic acid salt inclusion compound and preparation methods thereof.CN Patent 101935319A2011
  173. TsengP.-Y. BrownC. O. Therapeutic uses of berberine formulations.US Patent 10213418B22019
  174. CuiY. ZhangY. Berberine cyclodextrin inclusion compound, preparation thereof and preparation method.CN Patent 101461949B2011
  175. LiuS. QiL. Berberine hydrochloride eutectic crystal, preparation method and application thereof.CN Patent 108558861B2021
  176. JiY.C.Y. Synthesis method and application of taxol-berberine nano-drug.CN Patent 110251685B2022
  177. HanZ. Berberine hydrochloride taste-masked pellet, and preparation thereof.CN Patent 104997735A2015
  178. WangP.-L. Berberine formulations and uses thereof.US Patent 9427432B22016
  179. WuH. LiJ. BuC. Compound preparation of berberine hydrochloride.CN Patent 101467999A2009
  180. WaveD. Berberine-phenylacetic acid derivative, its pharmaceutically acceptable salt and synthetic method.CN Patent 102229607A2011
  181. YangL. GuanhuaD. JunziC. ShiyingY. Eutectic compound of berberine hydrochloride and fumaric acid, preparation method, composition and application thereof.CN Patent 110041326B2022
  182. YaS. TanJ. ZhouZ. Berberine hydrochloride granule for masking flavor and its preparation.CN Patent 1273133C2006
  183. AnetaB. JiriL. Manufacturing method of oral dosage form containing berberine, oral dosage form containing berberine and use thereof.WO Patent 2019024949A12019
  184. YangS. MeiX. LiX. Berberine hydrochloride solid lipid nano preparation and preparation method thereof.CN Patent 102949375B2015
  185. HuL. JiaL. 13, 13a- dihydro berberine derivant and pharmaceutical composition.CN Patent 101153039B2010
  186. TengH. WeiW. ZheL. Mangiferin-berberine salt, manufacturing method and use thereof.CN Patent 102753185B2014
  187. LiuL. Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof.AU Patent 2019222911B22021
  188. GabrieleJ. BaranowskiD. BuchananB. ZuccoloJ. TerisM. Transdermal formulations for delivery of berberine compounds, and their use in the treatment of berberine-responsive diseases and conditions.US Patent 20180235870A12018
  189. WengW. HuangJ. ShentengQ.B. ZhangJ. XuH. GuoJ. Aliphatic organic acid salt of berberine type alkaloid and preparation method and usage thereof.CN Patent 101113149B2011
  190. TangJ. FanX. A kind of Berberine electrostatic complexes and preparation method thereof.CN102702190B2016
  191. TengH. WuW. ZhangJ.Z. LinZ. Mangiferin-6-O-berberine salt and preparation method and use thereof.US Patent 10285969B22019
/content/journals/npj/10.2174/0122103155324599241028163050
Loading
Exploring Pharmacological Mechanisms, Clinical Trials and Patent Landscapes of Berberine: A Review
Natural Products Journal, The 16, E22103155324599 (2026); https://doi.org/10.2174/0122103155324599241028163050
/content/journals/npj/10.2174/0122103155324599241028163050
/content/journals/npj/10.2174/0122103155324599241028163050
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): cancer; clinical data; Diabetes mellitus; neuro-effectiveness activity; patent study; source

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test